Sign up
Pharma Capital

VentriPoint's VMS System used to test 500 Sarcoidosis patients in Netherlands

Ventripoint Diagnostics (CVE:VPT-OTCQB-VPTDF) CEO George Adams  joined Steve Darling from Proactive Investors Vancouver on Skype with news their VMS System was used to study patients with Sarcoidosis, an inflammatory disease that affects multiple organs in the body, including the heart.

Adams told Proactive how many patients where in the study and how the company will be using this data going forward. Adams also had an update on what the company will be doing in China in 2019.

 

View full VPT profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.